OmniAb, Inc. Stock Price, News & Analysis

OmniAb, Inc. (NASDAQ: OABI) announced its participation in five investor conferences throughout May 2023. Highlights include:

• H.C. Wainwright BioConnect Investor Conference on May 2, 2023, featuring a fireside chat at 9:30 a.m. ET and one-on-one meetings in New York City.
• E.F. Hutton Global Conference on May 10-11, 2023, with one-on-one meetings on May 11 at The Plaza Hotel, New York City.
• Benchmark 3rd Annual Virtual Healthcare House Call on May 23, 2023, hosting virtual one-on-one meetings.
• B. Riley Securities 23rd Annual Institutional Investor Conference on May 24-25, 2023, with meetings on May 24 in Beverly Hills.
• Craig-Hallum 20th Annual Institutional Investor Conference on May 31, 2023, at The Depot Renaissance Minneapolis Hotel.

OmniAb's platform supports pharmaceutical partners in discovering next-generation therapeutics via diverse antibody repertoires.

OmniAb, Inc. (NASDAQ: OABI) reported strong financial results for Q4 and full-year 2022, with Q4 revenue of $35.3 million, up from $15.3 million in Q4 2021, driven by a $25 million milestone from TECVAYLI™ sales. Full-year revenue reached $59.1 million, an increase from $34.7 million in 2021. Despite net losses of $22.3 million for 2022, improved from a loss of $27 million in 2021, the company ended the year with $88.3 million in cash. OmniAb also signed 13 new partnerships and has 69 active partners pursuing 291 programs. The company anticipates recognizing $10 million more in milestone payments in 2023, showcasing a robust pipeline and growth potential.

OmniAb, Inc. (NASDAQ: OABI) will release its financial results for the three and 12 months ending December 31, 2022 on March 30, 2023, after market close. A conference call to discuss these results and business updates is scheduled for the same day at 4:30 p.m. Eastern time. Investors can join the call in the U.S. at (888) 886-7786 or internationally at +1 (416) 764-8658, using conference ID 43857264. A live and replay webcast will be available here.

OmniAb, Inc. (NASDAQ: OABI) has announced participation in three investor conferences. The first is the SVB Securities Global Biopharma Conference from February 14-16, 2023, featuring a virtual fireside chat on February 15 at 11:20 a.m. Eastern time. Next, at the Cowen 43^rd Annual Health Care Conference from March 6-8, 2023 in Boston, management will present on March 8 at 9:50 a.m. Eastern time. Lastly, they will host one-on-one meetings at the 35^th Annual Roth Conference from March 12-14, 2023. Details of the presentations will be available on their website.

OmniAb, Inc. (NASDAQ: OABI) announced participation in two investor conferences. The Credit Suisse 31st Annual Healthcare Conference will take place from November 7-10, 2022 in Rancho Palos Verdes, California, featuring a fireside chat on November 9 at 11:35 a.m. PT. The Stifel Healthcare Conference is scheduled for November 15-16, 2022 in New York City, with management presenting on November 15 at 4:45 p.m. ET. Both events will include one-on-one investor meetings and webcasts available on OmniAb's website.

OmniAb, Inc. (NASDAQ: OABI) announced the commencement of regular trading on November 2, 2022. CEO Matt Foehr will ring the Nasdaq opening bell at 9:30 a.m. Eastern time to celebrate the company's spin-off from Ligand Pharmaceuticals. Foehr expressed gratitude to stakeholders and emphasized the company's commitment to enhancing shareholder value through advanced antibody discovery technologies. The event will be livestreamed, marking a significant milestone for OmniAb as an independent publicly-traded entity.

Ligand Pharmaceuticals has completed the spin-off of its OmniAb antibody discovery business, now known as OmniAb, Inc., which will begin trading on NASDAQ under the symbol 'OABI' from November 2, 2022. Ligand continues under the ticker 'LGND'. CEO John Higgins emphasized Ligand's focus on financial growth and highlighted a diversified portfolio of royalty revenues and late-stage programs. Executive updates include Matt Korenberg promoted to President and COO, Tavo Espinoza as CFO, and Andrew Reardon as Chief Legal Officer. Ligand will relocate its headquarters to Las Vegas, Nevada.